Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China's Leading Medical Equipment Maker Succeeds - Where Others Stumble - In Merging With U.S. Competitor

This article was originally published in PharmAsia News

Executive Summary

BEIJING - China's leading developer of medical devices, Mindray Medical International, is emerging as the golden success story in terms of a Chinese enterprise taking over an American competitor in the life sciences arena, with a 15.8 percent jump in net revenues for 2009 to $634.2 million

You may also be interested in...



China’s Mindray Expands Market With Increased R&D And Acquisitions

Mindray expects to hold its own amidst foreign competition, including in the high-end device market thanks to acquisitions and R&D investments that have boosted its technological capability.

Kanghui Bullish On Joint Implants Despite Looming Price Cuts; Mindray Undercutting U.S. Competition: China Earnings Roundup (Part 4)

Regulatory headwinds and price cuts led to a massive slowdown in China’s pharmaceutical industry in Q3, but China’s device makers are still enjoying fast growth.

China's Leading Device Maker Mindray Projects Strong Earnings Despite Instability Across The Middle East

BEIJING - Despite instability in the Middle East and North Africa, the leadership of Mindray Medical International is pressing ahead with plans to expand sales in international markets and is projecting a rise in net earnings of more than 10% in 2011

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC074254

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel